Please assess the completion status of the following clinical trial:

Trial Title: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus~* Glycosylated Hemoglobin (HbA1c) between 6.5 and 10% (inclusive)~* Current therapy with ACEi or ARB at stable dose for 10 weeks~* Urinary albumin-to-creatinine ratio (UACR): 30-3000 mg/g creatinine documented in the previous 12 months or detected at Screening.~* Estimated Glomerular Filtration Rate (eGFR) greater than 30 ml/min.~* Age between 18 and 80 years.~Exclusion criteria:~* Dual or triple blockade of the Renin Angiotensin System (RAS)~* Uncontrolled hyperglycaemia~* Mean arterial blood pressure \> 110 mmHg~* Known hypersensitivity or allergy to the investigational product, or their excipients (including matching placebos).~* Treatment with a glitazone within 6 months prior to informed consent.~* Treatment with a DiPeptidyl-Peptidase 4 (DPP-4) inhibitor, a Glucagon Like Peptide-1 (GLP-1) agonist, a Sodium/Glucose coTransporter 2 (SGLT2) inhibitor, a dopamine-agonist, a bile-acid sequestrant a short acting (prandial) insulin or premixed insulin within 10 weeks prior to informed consent.~* Treatment with anti-obesity drugs 10 weeks prior to informed consent.~* Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.~* Current treatment with systemic steroids (glucocorticoids) at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.~* Participation in another trial with an investigational drug within 2 months prior to informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin 5mg (Type: EXPERIMENTAL): linagliptin 5 mg once daily
- placebo (Type: PLACEBO_COMPARATOR): matching placebo for linagliptin dose once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).